New Injectable for Plaque Psoriasis

• Autores: Diane S. Aschenbrenner
• Localización: American Journal of Nursing, ISSN 0002-936X, Vol. 115, Nº. 5, 2015, págs. 23-24
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • * Secukinumab (Cosentyx) is a newly approved recombinant human monoclonal antibody used to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy (or both). Secukinumab is administered subcutaneously, either by the patient or a provider.

    * The most common adverse effects include diarrhea, nasopharyngitis, and upper respiratory infections. Those who receive secukinumab may also have severe allergic reactions and have an increased risk of developing infections.